Lower stroke and MI risk with pioglitazone in T2DM

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1607, 2007-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone improves measures of T2DM and dyslipidaemia

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Pioglitazone a star performer in the T2DM arena?

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Pioglitazone economically attractive for type 2 DM in Canada

Inpharma, Vol. 1, Iss. 1331, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Pioglitazone economically attractive for type 2 DM in Canada

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 356, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Pioglitazone provides greater long-term glycaemic control than glibenclamide [glyburide] in patients with type 2 diabetes mellitus (T2DM)

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite